8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
The Type 2 diabetes (T2D) market is a crowded and competitive landscape with multiple ‘me-too’, generic and biosimilar drugs entering the sector. Growth will be primarily driven by the launch of novel blockbuster therapies and an increasing diagnosed prevalent population across the nine major markets. (9MM). 14 January 2023
The US Food and Drug Administration (FDA) has approved a label update for Rybelsus (semaglutide) tablets 7mg or 14mg, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment. 13 January 2023
Fatal cases of acute liver failure reported in patients treated with Zolgensma (onasemnogene abeparvovec) were raised this week at the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). 13 January 2023
A Phase III trial miss has hollowed out the share price of Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals. 13 January 2023
Shares of India’s largest biotech firm Biocon slumped 2.4% to record a new 52-week low, after its subsidiary Biocon Biologics informed that the US Food and Drugs Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for its Insulin-R product. 13 January 2023
US a multi-asset longevity biotech Cambrian Biopharma yesterday unveiled its latest pipeline company, as Isterian Biotech. emerged from stealth, headquartered in New York. 13 January 2023
The US Food and Drug Administration’s (FDA) recent approval of TG Therapeutics’ Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a major setback in 2022 when the FDA extended its review of Briumvi by three months. 13 January 2023
A sudden surge in Covid cases in China has made anti-Covid generic drugs from India attractive, including the generic version of Pfizer's anti-Covid oral drug Paxlovid (nirmatrelvir/ritonavir), which is in high demand and needs to be reserved weeks in advance, reports The Pharma Letter's local correspondent, 12 January 2023
China’s National Medical Products Administration (NMPA) has approved Japanese pharma giant Takeda’s Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. 12 January 2023
French pharma major Sanofi has announced an additional multi-year commitment into its evergreen venture fund, with an increase in capital to more than $750 million. 12 January 2023
Administrators at the US Department of Health and Human Services (HHS) have announced key dates in its planned negotiation of certain prescription drug prices available through Medicare. 12 January 2023
US neuromuscular and cardiac diseases specialist Solid Biosciences and privately-held Dutch biotech Phlox Therapeutics have announced a strategic collaboration focused on genetic cardiac diseases. 12 January 2023
Pittsburgh, USA-based clinical-stage biotech Lipella Pharmaceuticals’ shares rose as much as 76% to $5.48, after it announced positive trial results with its bladder disease candidate. 12 January 2023
Singapore-based Novotech, the leading Asia-Pacific centered biotech contract research organization (CRO), has acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. 12 January 2023
Research from industry analyst GlobalData finds that western companies are likely to play an important role in providing new cardiovascular disease (CVD) management options in China. 12 January 2023
The Kerela High Court in India has directed the Department for Promotion of Industry and Internal Trade to consider compulsory licensing of breast cancer drug ribociclib. 11 January 2023
British biotech Pheno Therapeutics has announced a licensing deal with Belgium’s largest drugmaker UCB, focusing on the science of remyelination. 11 January 2023
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.